Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Molnupiravir
Nigella Sativa
Nitazoxanide
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
All studies
Mortality
Hospitalization
Serious outcomes
Viral clearance
RCTs
RCT mortality
All outcomes

Feedback
Home   COVID-19 treatment studies for Molnupiravir  COVID-19 treatment studies for Molnupiravir  C19 studies: Molnupiravir  Molnupiravir   Select treatmentSelect treatmentTreatmentsTreatments
Aspirin Molnupiravir
Bamlanivimab Nigella Sativa
Bromhexine Nitazoxanide
Budesonide Povidone-Iod..
Casirivimab/i.. Probiotics
Colchicine Proxalutamide
Conv. Plasma Quercetin
Curcumin Remdesivir
Favipiravir Sotrovimab
Fluvoxamine Vitamin A
Hydroxychloro.. Vitamin C
Iota-carragee.. Vitamin D
Ivermectin Zinc
Melatonin

Other Adoption
Outcomes in COVID-19 molnupiravir studies
00.250.50.7511.251.51.752+Fischer (RCT)77%0.23 [0.01-5.69]death0/1401/62Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment77%0.23 [0.01-5.69]0/1401/6277% improvementAll studies77%0.23 [0.01-5.69]0/1401/6277% improvement1 molnupiravir COVID-19 studyc19mp.com Sep 24, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 0.89Effect extraction pre-specifiedFavors molnupiravirFavors control 00.250.50.7511.251.51.752+Fischer (RCT)77%0.23 [0.01-5.69]0/1401/62Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment77%0.23 [0.01-5.69]0/1401/6277% improvementAll studies77%0.23 [0.01-5.69]0/1401/6277% improvement1 molnupiravir COVID-19 mortality resultc19mp.com Sep 24, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 0.89Favors molnupiravirFavors control 00.250.50.7511.251.51.752+Fischer (RCT)-33%1.33 [0.14-12.5]hosp.3/1401/62Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment-33%1.33 [0.14-12.5]3/1401/62-33% improvementAll studies-33%1.33 [0.14-12.5]3/1401/62-33% improvement1 molnupiravir COVID-19 hospitalization resultc19mp.com Sep 24, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 0.25Favors molnupiravirFavors control 00.250.50.7511.251.51.752+Fischer (RCT)77%0.23 [0.01-5.69]death0/1401/62Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment77%0.23 [0.01-5.69]0/1401/6277% improvementAll studies77%0.23 [0.01-5.69]0/1401/6277% improvement1 molnupiravir COVID-19 serious outcomesc19mp.com Sep 24, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 0.89Effect extraction pre-specifiedFavors molnupiravirFavors control 00.250.50.7511.251.51.752+Fischer (RCT)49%0.51 [0.22-1.18]viral+10/1189/54Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment49%0.51 [0.22-1.18]10/1189/5449% improvementAll studies49%0.51 [0.22-1.18]10/1189/5449% improvement1 molnupiravir COVID-19 viral clearance resultc19mp.com Sep 24, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 1.58Favors molnupiravirFavors control 00.250.50.7511.251.51.752+Fischer (RCT)77%0.23 [0.01-5.69]death0/1401/62Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment77%0.23 [0.01-5.69]0/1401/6277% improvementAll studies77%0.23 [0.01-5.69]0/1401/6277% improvement1 molnupiravir COVID-19 Randomized Controlled Trialsc19mp.com Sep 24, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 0.89Effect extraction pre-specifiedFavors molnupiravirFavors control 00.250.50.7511.251.51.752+Fischer (RCT)77%0.23 [0.01-5.69]0/1401/62Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment77%0.23 [0.01-5.69]0/1401/6277% improvementAll studies77%0.23 [0.01-5.69]0/1401/6277% improvement1 molnupiravir COVID-19 RCT mortality resultc19mp.com Sep 24, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 0.89Favors molnupiravirFavors control 00.250.50.7511.251.51.752+Fischer (RCT)77%0.23 [0.01-5.69]death0/1401/62Improvement, RR [CI]TreatmentControlFischer (RCT)65%0.35 [0.01-8.33]death0/551/62Fischer (RCT)67%0.33 [0.01-8.03]death0/621/62Fischer (RCT)58%0.42 [0.02-10.0]death0/231/62Fischer (RCT)-33%1.33 [0.14-12.5]hosp.3/1401/62Fischer (RCT)-13%1.13 [0.07-17.6]hosp.1/551/62Fischer (RCT)-100%2.00 [0.19-21.5]hosp.2/621/62Fischer (RCT)58%0.42 [0.02-10.0]hosp.0/231/62Fischer (RCT)49%0.51 [0.22-1.18]viral+10/1189/54Fischer (RCT)89%0.11 [0.01-0.86]viral+1/539/54Fischer (RCT)30%0.70 [0.25-1.93]viral+5/439/54Fischer (RCT)-9%1.09 [0.37-3.18]viral+4/229/54Fischer (RCT)92%0.08 [0.01-0.62]viral+1/1176/54Fischer (RCT)92%0.08 [0.00-1.34]viral+0/536/54Fischer (RCT)91%0.09 [0.00-1.48]viral+0/426/54Fischer (RCT)59%0.41 [0.05-3.20]viral+1/226/54Fischer (RCT)30%0.70 [0.37-1.36]viral+19/13712/61Fischer (RCT)62%0.38 [0.13-1.12]viral+4/5312/61Fischer (RCT)-8%1.08 [0.54-2.18]viral+13/6112/61Fischer (RCT)56%0.44 [0.11-1.83]viral+2/2312/61molnupiravir COVID-19 outcomesc19mp.com Sep 24, 2021Favors molnupiravirFavors control
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit